CRL has consistently achieved ROE values above 12% since 2018. In addition, in the same period, its liabilities-to-assets ratio has exhibited a downward trend. The company has seen a considerable ...
Despite an FDA advisory committee’s narrow ruling that Provention Bio Inc.’s teplizumab has benefits that outweigh the risks in treating diabetes, the agency sent the company a complete response ...
The U.S. FDA declined to approve Gilead Sciences Inc.’s Hepcludex (bulevirtide), issuing a complete response letter (CRL) citing manufacturing and delivery concerns for the antiviral aimed at treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results